Introduction
============

Congenital hemophilia (CH) is a rare disease resulting from a deficiency of coagulation factor VIII in patients with hemophilia A (CHA) or of factor IX in patients with hemophilia B (CHB). Approximately 18,000 individuals in the United States have been diagnosed with CH.[@b1-jbm-3-131] The standard treatment is replacement of the deficient coagulation factors; however, alloantibodies/inhibitors to factor replacements develop in 15% to 30% of CHA patients and in 3% to 5% of CHB patients.[@b2-jbm-3-131],[@b3-jbm-3-131] Currently, there are approximately 800 known CH patients with inhibitors (CHwI) in the United States.[@b1-jbm-3-131]

The presence of inhibitors in CH patients often results in greater difficulty in controlling bleeding episodes as well as frequent bleeding into joints, which leads to arthropathy, pain, and disability. Treatment for bleeding episodes in these patients is different from that for other CH patients since standard factor replacement is not effective. Acute bleeding episodes in CHwI patients are managed with bypassing agents, such as recombinant factor VIIa (rFVIIa) (NovoSeven^®^ RT, Novo Nordisk A/S, Bagsvaerd, Denmark) and plasma-derived activated prothrombin complex concentrate (FEIBA VH^®^, Baxter AG, Vienna, Austria), rather than with factor replacements. Treatment is also more complex in CHwI than in CH patients, who usually receive only one or two doses of replacement coagulation factors for each bleeding episode. In contrast, CHwI patients may require multiple doses over several days to resolve a single bleeding episode.

Although treatment for bleeding episodes is administered intravenously, nearly all treatments are given in the home setting. Furthermore, regimens are often based on a combination of physician recommendations and the experience of the patient and caregiver. Consequently, actual treatment patterns and their impact on CHwI patients and their families are largely unrecorded and poorly understood.

Patient diaries are useful tools for collecting patient-reported information about disease condition, treatment, and health-related quality of life (HRQoL). Daily diary assessments have been conducted in a variety of conditions, often focusing on a specific aspect of patient-reported outcomes, such as functional impairment, symptoms, or well-being. Among these studies, a small but growing number have incorporated HRQoL measures into daily diaries;[@b4-jbm-3-131]--[@b9-jbm-3-131] however, few studies have evaluated daily HRQoL using generic measures such as the EQ-5D, from which a profile of health and index-based utility scores are generated. Despite the availability of many stand-alone handheld diary devices and Web-based diaries, published evidence that informs the use of these measures via electronic data capture is limited, particularly in CHwI patients.

The objective of the Dosing Observational Study in Hemophilia (DOSE) was to facilitate our understanding of how rFVIIa and other coagulation factor products are used in CHwI patients prescribed first-line rFVIIa in the home setting;[@b10-jbm-3-131] the patient/caregiver decision-making process around bleed recognition and treatment;[@b11-jbm-3-131] and the impact on HRQoL[@b12-jbm-3-131] and associated patient-centered issues, such as interference with work or school, time spent by the patient or caregiver administering the medication, and other major interference with the daily activities of the patient or caregiver. As the patient/caregiver reported data in this study are quite extensive and are being reported in detail elsewhere,[@b10-jbm-3-131]--[@b12-jbm-3-131] the purpose of this article is to evaluate the feasibility of the daily collection of these treatment outcomes as reported by CHwI patients or their caregivers, identify the key methodological issues related to study completion, provide overall descriptions of the relevant populations being assessed, and discuss the general limitations and applications of this approach that are consistent across all analyses.

Methods
=======

Ethics
------

The study was conducted in accordance with the Declaration of Helsinki and its amendments in force at the initiation of the study[@b13-jbm-3-131] as well as the Guidelines for Good Pharmacoepidemiology Practice.[@b14-jbm-3-131] It was conducted with prior approval by local institutional review boards and with written consent from the participants or their legal representatives. The participants were compensated for their contribution to the study, with additional compensation for those directly entering data in real time into the electronic diary format.

Study population
----------------

Patients with CHA or CHB with inhibitors who had at least four bleeding episodes of any type in the prior 3 months and who were prescribed rFVIIa as the first-line treatment or as the recommended therapy for bleeding episodes (including prescribed rFVIIa therapy for breakthrough bleeding on immune tolerance therapy \[ITT\] or prophylaxis) were eligible for the study. Patients were consented and enrolled by study sites after screening against inclusion/exclusion criteria, and then were trained and provided diaries. In parallel to patient enrollment, sites reported on patient demographics, hemophilia history, and current prescriptions.

Study design
------------

The study was conducted from January 2008 to July 2009 at 20 study sites in the United States, all of which were federally designated hemophilia treatment centers. The patients or their caregivers participated in the diary study for at least 90 days and until patients experienced at least four bleeding episodes.

Daily diary
-----------

The daily diary was developed in association with health care professionals (eg, physicians and nurses), CHwI patients, and caregivers who all provided insight into categorical responses for all descriptive fields to minimize free-text fields. Daily diary assessments recorded information on bleeding status, interference with planned activities, and QoL assessments (EQ5D-3L, visual analog scale \[VAS\] health, VAS pain) ([Table 1](#t1-jbm-3-131){ref-type="table"}). Permission was obtained from the EuroQol Group to use the standard EQ5D-3L (index score and VAS health) on a daily basis. Additional information was recorded on the days a patient had a bleeding episode or reported ongoing treatment for bleeding, even if the bleeding episode had already ended. Specifically, details of bleeding episodes, bypassing treatment administered, time spent mixing and administering agents, pain levels at the time of each dose, and HRQoL information were recorded on bleed forms ([Table 1](#t1-jbm-3-131){ref-type="table"}). Absenteeism from planned daily activities was measured by the percentage of missed or unproductive bleed days that occurred on scheduled work or school days for the participant, as reported in the daily diary entries. The study participants were encouraged to save and submit the bar codes from box tops of bypassing agents used to validate diary reporting by verifying that the dose reported correlated with product use.

Primary diaries were kept on paper. Additional Internet-based entry was optional. Electronic diaries were submitted online in real time, whereas paper diaries were submitted monthly to the dedicated patient support liaison personnel at the contract research organization. The standardized 10 cm VAS was used in the paper diaries and was transferred to the electronic diaries as a number. Paper-only diaries were entered into electronic diary format by the contract research organization.

Patient and caregiver support
-----------------------------

Throughout the study, independent dedicated patient support liaison personnel provided logistical support to the patients and their caregivers, and contacted them regarding training, data clarification, overdue forms, product box tops, and additional bleed forms.

Data validation
---------------

Data validation was performed throughout the study by comparing electronic diaries with paper diaries (for participants who recorded both), comparing product box tops with bleed diaries, making telephone or email contact with participants, and reviewing paper diaries for inconsistencies.

Because Web-based entry of VAS health scores as an integer on a 0--100 scale had not been validated, a preplanned comparison of the reported VAS on the 10 cm scale, with the number reported, was performed. For 53% of diary days with electronic EQ-5D VAS assessments, correlations between paper- and Web-based responses were manually analyzed to determine any discrepancies between the two diary platforms.

Results
=======

Patient disposition
-------------------

Fifty-two patients (25 pediatric, 27 adult) were enrolled ([Table 2](#t2-jbm-3-131){ref-type="table"}), representing 7% of the approximately 800 CHwI patients in the United States. The historical use of rFVIIa to control acute bleeding by the enrolled patients included on-demand treatment (37 patients), control of breakthrough bleeds while on bypassing agent prophylaxis (10 patients), control of breakthrough bleeds while on ITT (three patients), and control of breakthrough bleeds while on ITT or bypassing agent prophylaxis.[@b2-jbm-3-131] As expected, ITT was more common in the pediatric population; prophylaxis was also more common in this group. The median duration of study participation was 91 days. This was similar for both caregiver-completed diaries for pediatric patients (91 days) and for adult patients (108.5 days) ([Table 3](#t3-jbm-3-131){ref-type="table"}). Analysis of patient histories provided by the study sites in parallel with patient enrollment revealed two patients prescribed plasma-derived activated prothrombin complex concentrate as first-line therapy and two patients with a history of less than four bleeds in the past year.

Patient support and communication
---------------------------------

Each participant was contacted by email or telephone at least once weekly by the dedicated patient support liaison personnel. There were 758 communications (average 15 contacts per participant) in total, with the majority (624 contacts \[82%\]) made during the diary entry period ([Table 4](#t4-jbm-3-131){ref-type="table"}).

Diary completion and diary days
-------------------------------

Diaries were completed by 75% (39/52) of the enrolled participants (19 caregivers on behalf of 21 pediatric patients, 18 adult patients), resulting in a total of 4063 diary days ([Tables 2](#t2-jbm-3-131){ref-type="table"} and [5](#t5-jbm-3-131){ref-type="table"}). Enrolled pediatric patients included two sets of siblings whose diaries were reported by their caregivers. Adult patient-reported diary days accounted for 2059 total diary days and caregiver-reported diary days accounted for 2004 total diary days. There were 3776 potential diary days for patients and caregivers who opted in to track daily HRQoL evaluations.

Twenty-three (59%) participants completed both paper and electronic diaries, resulting in 2529 (62%) paper-and-electronic diary days. Both patients and their caregivers completed more paper-and-electronic diaries than paper-only diaries ([Table 5](#t5-jbm-3-131){ref-type="table"}).

Bleed days
----------

Only a small proportion of the diary days were bleed days (mean/median per patient: 13.9%/8.2%) (491 bleed days; 194 bleeding episodes) or treatment days (mean/median per patient: 13.1%/8.2%). The majority of these bleeds were spontaneous (57.4%) and located in the joint (69.7%) for all the treatment groups ([Table 6](#t6-jbm-3-131){ref-type="table"}). Only one patient completing a diary did not experience a bleeding episode during the study period ([Table 2](#t2-jbm-3-131){ref-type="table"}). Patients in the on-demand group reported a smaller proportion of bleed days and bleed treatment days than did patients in the ITT and prophylaxis groups ([Table 3](#t3-jbm-3-131){ref-type="table"}). Adult patients reported a smaller proportion of bleed days and treatment days than did children ([Table 3](#t3-jbm-3-131){ref-type="table"}).

Quality of life
---------------

Quality-of-life assessments, including EQ5D-3L, VAS health, and VAS pain ([Table 1](#t1-jbm-3-131){ref-type="table"}), on both bleeding and non-bleeding days were completed by 37 of 39 enrolled patients ([Table 2](#t2-jbm-3-131){ref-type="table"}) for 3771 of the 3776 eligible diary days completed by these patients or their caregivers (472 bleed days and 3299 non-bleed days). Half the bleed days recorded in this study were not planned work or school days for all patients (53%) and caregivers (48%), and therefore, were not eligible to be classified as being missed or unproductive.

There was an exact agreement between electronic and paper records for 93% of the EQ-5D VAS scores reviewed. The remaining scores were within either 1 mm or 2 mm above (5% of VAS scores) or below (2% of VAS scores) the actual measurement.

Discussion
==========

The congenital hemophilia inhibitor patient population is very small, both in the United States and globally. Hence, the opportunities for collecting information directly from patients are limited to some extent. As treatment has shifted to a home treatment paradigm, the need for an information flow from patients to their physicians and other caregivers has become more urgent. Furthermore, the extensive experience of patients and caregivers in managing their disease is a wealth of information that could benefit the advancement of treatment in this therapeutic area and inform clinical decision making in practice. Patient-reported diaries could be a useful addition to the comprehensive care that these patients receive from their hemophilia treatment centers; however, in practice, available paper or electronic bleed logs are poorly adhered to and poorly maintained by hemophilia patients.[@b15-jbm-3-131] Daily assessments of HRQoL could also provide valuable data useful in interpreting clinical trial outcomes and generating quality-adjusted life-year data for economic evaluations.

A first step toward the widespread use of electronic data capture of patient-centered outcomes in hemophilia is gathering of evidence to support its feasibility, validity, and reliability. The diaries reported in this study showed that categorical data did not capture all the necessary information from the diary responder. Handwritten comments in the margins of the paper diaries indicated that allowances must be made in the diaries for unforeseen circumstances, such as overlapping bleeding episodes or prophylaxis doses on days of acute bleeding.

The electronic reporting platform was used by two-thirds of the responders. The ability to perform real-time tracking and the assistance that responders could receive using this medium may have contributed to its high usage. While the majority of responders were clearly comfortable using the electronic diary, access to the Internet may still be a limitation for some patients. Alternative solutions could include the use of independent Internet-accessible devices (eg, smart phones) or Internet-enabled tablets (eg, netbooks).

No major difficulties were encountered by the study participants regarding the completion of the questionnaires on QoL and interference with work or school. Excellent agreement between the paper and electronic versions of the VAS scale was observed, which suggests that the different modes of data collection may be interchangeable without a loss of reliability in these patients. Daily HRQoL assessments appeared to be feasible and may improve the accuracy of the information obtained, given the infrequency of bleed days observed in this study. Periodic assessments would likely have resulted in sampling only the baseline in this population. In contrast, daily HRQoL provided significant new insight into daily issues, both at baseline and during bleeding episodes. Another important aspect of the evaluations of absences from work or school in this study was the tracking and use of "eligible" diary days that reported a more realistic impact of bleeding on the interruption of planned work or school activities while highlighting the impact of the disease by demonstrating that about half the patients and caregivers were not routinely working or attending school. Disability and restricted physical independence are frequent developments in patients with hemophilia and could have deleterious effects on the employment of caregivers, particularly for those with more than one child with hemophilia. While this study was conducted throughout the calendar year and included young children (pre-elementary), and hence may have been partially confounded by school vacation periods and summer recess, the timing in relation to the school and daycare calendar is an important consideration for future studies aimed at collecting information of this nature. Furthermore, the high percentage of nonworking or non-school days is partly attributable to weekends and public holidays, a fact that should also be accounted for in future diary programs. Other measures that capture patient disability and the family burden of multiple children with CHwI could also be included in future questionnaires, including the expansion of the novel assessment of family activity changes, anxiety, and stress into a true caregiver burden scale.

The firewalled patient support liaison component (in which only contract research organization personnel had access to patient contact information) was critical to the success of this study, as it likely increased the diary completion rates and improved the quality of the results through frequent patient and caregiver contact from the dedicated patient support liaison personnel, who developed a good rapport with these participants. One limitation of this study was the small study population. It is unclear how many of the approximately 800 CHwI patients in the United States have, on average, less than one bleeding episode per month and hence were excluded from this study. Although the diary completion rate was promising, a higher completion rate could have provided more comprehensive data. Another limitation was the fact that the majority of the patients were recruited from hemophilia treatment centers that had a larger patient pool and better resources to facilitate trials than others. These patients may not be representative of the majority of CHwI patients in the United States, and including patients from smaller treatment centers could have reduced the bias in the patient sample.

Although the objective of this article was to present and discuss the feasibility of daily diaries in CHwI patients, several points of interest deserve brief mention. (These topics will be discussed in greater detail in subsequent publications.) One is the higher percentage of bleed days and treatment days recorded in the ITT and prophylaxis groups, despite the fact that these data were only recorded on bleed days. A second observation is the similar distribution of bleed types and bleed locations among the on-demand, ITT, and prophylaxis groups, with spontaneous bleeds in the joints being the most common.

While our experience with the DOSE study proves the feasibility of obtaining patient-reported data in rare populations, the detailed analysis of primary and secondary endpoints from DOSE identifies issues that deserve further exploration through more focused patient-reported capture techniques. In an analysis of bleed symptoms and the reasons for initiating and discontinuing treatment, Valentino et al[@b11-jbm-3-131] found that bleed resolution is difficult for adults and caregivers, particularly, to identify -- an insight that might explain the sometimes longer treatment seen in observational studies than in clinical trials with fixed regimens. Comparing prescribed dosing with actual treatment, Young et al[@b10-jbm-3-131] found that there was variability of patient dosing (dose, interval, and duration of treatment) compared with a single prescribed regimen for both children and adults, and identified the need to capture a range of recommended treatments for different scenarios in future studies. In looking at daily EQ-5D and pain data, Neufeld et al[@b12-jbm-3-131] confirmed bleed (versus non-bleed) days and adult (versus pediatric) patients have worse HRQoL than non-bleed days, but identified that for adults with arthropathy, pain and HRQoL vary day to day, even without bleeds, challenging the paradigm of periodic QoL scores.

Conclusion
==========

This study supports the feasibility and reliability of daily diary completion by CHwI patients and their caregivers. The data provides insight into the home treatment of these patients as well as the impact of hemophilia on patients and their families. A high diary-completion rate was facilitated by dedicated patient support personnel and motivated participants. One limitation of the electronic diary platform was the use of categorical responses to eliminate free text. Because the handwritten details recorded in the margins of paper diaries were crucial for identifying overlapping bleeds, a section for open-ended comments may improve the ease of future interpretation of electronic diaries. Detailed analysis of the results highlight the need to continue developing patient-reported outcomes and caregiver instruments to continue exploring life with hemophilia.
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###### 

Information recorded in the daily diary and bleed day diary assessments

  Daily diary assessments                                                                                                Bleed day diary assessments (bleed forms)
  ---------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bleed status -- Started-- Stopped-- Continued                                                                          Details of the bleeding episode -- Bleed identification-- Cause-- Location-- Type of bleed-- Time of bleed onset and resolution-- Reasons for considering that a bleeding episode had stopped
  Work or school day status (Yes or No) -- Patient work or school day-- Caregiver work day                               Details of bypassing treatment administered -- Reasons for initiation of treatment-- Reasons for dose and dose interval selection-- The number of vials of bypassing agent used on an hour-by-hour basis-- Overall subjective assessment at time of each dose-- Effectiveness, dosage, and number of recombinant activated factor VII doses used-- Duration of mixing and infusion time for each agent at each infusion
  Optional EQ-5D assessments -- Mobility-- Self-care-- Daily activities-- Pain and discomfort-- Anxiety and depression   Activity interference assessment -- Lost patient or caregiver school or work time-- Changes to patient's or family's planned activities
  Visual analog scale scoring of -- Overall health-- Overall pain                                                        Details of concomitant pain medications used
  Family anxiety and stress rating                                                                                       Pain assessment -- At baseline-- At each dose
  Family planned activity interference assessment                                                                        

###### 

Patient disposition

                                                                                 Treatment group   All                                                                                        
  ------------------------------------------------------------------------------ ----------------- -------------------------------------------- --------------------------------------------- ----------------------------------------------------
  Enrolled patients[a](#tfn2-jbm-3-131){ref-type="table-fn"}                     37                5[a](#tfn2-jbm-3-131){ref-type="table-fn"}   12[a](#tfn2-jbm-3-131){ref-type="table-fn"}   52
  -- Pediatric (age ≤ 18)                                                        13                4                                            10                                            25
  -- Adult (age \> 18)                                                           24                1                                            2                                             27
  Diary completers[b](#tfn3-jbm-3-131){ref-type="table-fn"}, n (% of enrolled)   24 (64.9)         5 (100.0)                                    12 (100.0)                                    39 (75.0)[c](#tfn4-jbm-3-131){ref-type="table-fn"}
  -- Pediatric (age ≤ 18)                                                        9                 4                                            10                                            21
  -- Adult (age \> 18)                                                           15                1                                            2                                             18
  Patients with bleeding episodes, n (% completers)                              23 (95.8)         5 (100.0)                                    12 (100.0)                                    38 (97.4)
  -- Pediatric (age ≤ 18)                                                        8                 4                                            10                                            20
  -- Adult (age \> 18)                                                           15                1                                            2                                             18
  Patients with daily HRQoL assessments, n (% completers)                        22 (91.7)         5 (100.0)                                    12 (100.0)                                    37 (94.9)[c](#tfn4-jbm-3-131){ref-type="table-fn"}
  -- Pediatric (age ≤ 18)                                                        7                 4                                            10                                            19
  -- Adult (age \> 18)                                                           15                1                                            2                                             18
  Patients who completed 90 study days, n (% completers)                         20 (83.3)         4 (80.0)                                     8 (66.7)                                      31 (79.5)
  -- Pediatric (age ≤ 18)                                                        7                 3                                            7                                             16
  -- Adult (age \> 18)                                                           13                1                                            1                                             15

**Notes:**

Two enrolled patients had used both ITT and prophylaxis;

the diaries of adult patients were self-completed, whereas the diaries of pediatric patients were completed by their caregivers;

includes one patient with less than four bleeds in the past year.

**Abbreviations:** aPCC, activated prothrombin complex concentrates; HRQol, health-related quality of life; ITT, immune tolerance therapy.

###### 

Study duration and proportion of bleed and treatment days for diary completers[a](#tfn8-jbm-3-131){ref-type="table-fn"}

                                          Treatment regimen                                       Patient age   All                                        
  --------------------------------------- ------------------------------------------------------- ------------- ------------- ------------- -------------- --------------
  **Study duration per patient (days)**                                                                                                                    
  Number of patients                      24                                                      5             12            21            18             39
   Mean (SD)                              113.7 (33.6)                                            90.2 (1.3)    92.8 (16.9)   97 (23.0)     115.5 (33.8)   105.5 (29.6)
   Median                                 95                                                      91            91            91            108.5          91
   IQR                                    90--137                                                 90--91        83.5--95      90--91        90--141        90--124
   Range                                  74--180                                                 88--91        66--124       74--180       66--180        66--180
  **Proportion of bleed days (%)**                                                                                                                         
  Number of patients                      24                                                      5             12            21            18             39
   Mean (SD)                              10.5 (10.5)[\*](#tfn7-jbm-3-131){ref-type="table-fn"}   30.2 (25.6)   15.7 (12.5)   15.7 (16.0)   11.8 (13.3)    13.9 (14.8)
   Median                                 6.5                                                     26.1          9.5           8.9           5.9            8.2
   IQR                                    3.9--13.3                                               24.2--26.4    6.0--27.4     6.6--24.2     3.0--17.4      3.9--24.2
   Range                                  0.0--41.1                                               2.2--72.2     1.1--37.9     0--72.2       0.7--41.1      0.0--72.2
  **Proportion of treatment days (%)**                                                                                                                     
  Number of patients                      24                                                      5             12            20            18             38
   Mean (SD)                              8.5 (8.8)                                               30.2 (25.6)   17.3 (13.6)   15.7 (16.2)   10.1 (12.9)    13.1 (14.8)
   Median                                 6.5                                                     26.1          8.9           8.9           3.3            8.2
   IQR                                    2.7--11.7                                               24.2--26.4    6.6--26.6     6.6--25.2     2.2--14.1      3.3--16.7
   Range                                  0.0--34.4                                               2.2--72.2     2.0--45.5     0--72.2       0.7--45.5      0.0--72.2

**Notes:**

*P* = 0.0058 for mean percentage of bleed days for the on-demand only group vs mean percentage of bleed days for the ITT group;

the diaries of adult patients were self-completed, whereas the diaries of pediatric patients were completed by their caregivers.

**Abbreviations:** ITT, immune tolerance therapy; IQR, interquartile range; SD, standard deviation.

###### 

Communications between patient liaison personnel and patients/caregivers

                                                                 Paper diaries   Web diaries   Total
  -------------------------------------------------------------- --------------- ------------- ------------
  **All communications**                                                                       
  Total calls/emails/communications per patient communications   326             432           758
   Mean                                                          16.3            14.46         15.23
   Median (range)                                                12 (3--41)      13 (2--35)    13 (2--41)
  **Communications before start of diaries**                                                   
  Total calls/emails/communications per patient communications   59              75            134
   Mean                                                          2.95            2.39          2.63
   Median (range)                                                2 (0--12)       2 (0--13)     2 (0--13)
  **Communications after start of diaries**                                                    
  Total calls/emails/communications per patient communications   267             357           624
   Mean                                                          13.35           12.07         12.6
   Median (range)                                                10 (2--39)      11 (1--27)    11 (1--39)

###### 

Diary days completed by study participants

                                                                         Caregiver diaries[a](#tfn11-jbm-3-131){ref-type="table-fn"}   Adult diaries   All
  ---------------------------------------------------------------------- ------------------------------------------------------------- --------------- ------
  Number of diary responders[b](#tfn12-jbm-3-131){ref-type="table-fn"}   19                                                            18              39
  Number of diary patients                                               21                                                            18              
  Paper-only diary days                                                  839                                                           695             1443
  Paper and electronic diary days                                        1165                                                          1364            2620
  Total diary days                                                       2004                                                          2059            4063

**Notes:**

Two sets of siblings had diaries reported by their caregivers;

responders refer to the adult patients and caregivers of pediatric patients who completed the study diaries.

###### 

Causes and types of bleeding episodes

                                                     On demand              ITT                    Prophylaxis            All patients
  -------------------------------------------------- ---------------------- ---------------------- ---------------------- -----------------------
  Number of patients                                 23                     5                      12                     38
  Total number of bleeds                             101                    58                     59                     194
  **Cause of bleed, n (%)**                                                                                               
  Number of bleeds                                   97                     58                     57                     188
   Spontaneous                                       55 (56.7)              24 (41.4)              42 (73.7)              108 (57.4)
   Trauma                                            31 (32.0)              21 (36.2)              13 (22.8)              55 (29.3)
   Surgical procedure                                3 (3.1)                0 (0.0)                0 (0.0)                3 (1.6)
   Other                                             8 (8.2)                13 (22.4)              2 (3.5)                22 (11.7)
  Missing                                            4                      0                      2                      6
  **Type of bleed, n (%)**                                                                                                
  Number of bleeds                                   97                     58                     57                     188
   Target joint; all joint                           11 (11.3); 69 (71.1)   23 (39.7); 34 (58.6)   14 (24.6); 42 (73.7)   39 (20.7); 131 (69.7)
   Muscle                                            12 (12.4)              6 (10.3)               1 (1.8)                19 (10.1)
   External/skin                                     1 (1.0)                1 (1.7)                0 (0.0)                2 (1.1)
   Soft tissue                                       13 (13.4)              17 (29.3)              11 (19.3)              32 (17.0)
   Other[a](#tfn14-jbm-3-131){ref-type="table-fn"}   18 (18.6)              16 (27.6)              9 (15.8)               37 (19.7)
  Missing                                            4                      0                      2                      6

**Note:**

Other includes types of bleeds categorized as mouth/gums, nose, brain, and other.

**Abbreviation:** ITT, immune tolerance therapy.
